March 21, 2018 / 12:09 PM / a month ago

BRIEF-Arch Biopartners Granted Meeting With FDA For Candidate Drug

March 21 (Reuters) - Arch Biopartners :

* ARCH BIOPARTNERS GRANTED PRE-IND MEETING WITH FDA FOR CANDIDATE DRUG TO PREVENT ACUTE KIDNEY INJURY

* ARCH BIOPARTNERS INC - ‍PRE-IND MEETING WITH U.S. FDA DIVISION OF CARDIOVASCULAR AND RENAL PRODUCTS DCRP WILL TAKE PLACE ON APRIL 18, 2018​

* ARCH BIOPARTNERS - ‍SUBMITTED INFORMATION PACKAGE TO FDA DCRP CONTAINING QUESTIONS & DRAFT IND APPLICATION CONTENT​

* ARCH BIOPARTNERS - ‍MEETING FDA TO REVIEW, CONFIRM KEY COMPONENTS OF A PLANNED IND APPLICATION FOR METABLOK AS TREATMENT TO PREVENT ACUTE KIDNEY INJURY​ Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below